In this episode of ATTD 2026 Conference Catch-Up, we dive into Debate: HbA1c and Not CGM Should Be the Gold Standard to Evaluate Glucose Control, featuring a dynamic exchange of perspectives on the most accurate method for assessing glucose control in diabetes. Join us as we summarize key takeaways from these thought-provoking presentations: Pro – Dr. Elizabeth Selvin Con – Dr. Richard M. Bergenstal Moderator – Dr. Irl B. Hirsch This episode is an essential listen for endocrinologists, diabetes specialists, and healthcare professionals seeking insights into the ongoing debate between HbA1c and Continuous Glucose Monitoring (CGM) in evaluating glucose control. Gain a deeper understanding of the arguments for and against each method, and the implications for diabetes management. Enjoy the listen! This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information. ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11-14 March, 2026, in Barcelona. https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related